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Introduction. There are two binding sites on the β1-adrenoceptor (AR), β1H and β1L corresponding to high and low 
affinity binding sites respectively, which can be activated to cause cardiostimulation. Some β-blockers that block 
β1AR and β2ARs can activate β1LARs at higher concentrations than those required to cause blockade. The β2AR 
does not form a corresponding low affinity binding site and therefore we postulated that heterologous amino acids 
are responsible for the formation of β1LAR.  
Aim. To investigate whether heterologous amino acids of transmembrane domain V (TMDV) of β1AR and β2ARs 
contribute to β1LAR.  
Methods.  β1ARs, β2ARs and mutant β1ARs containing all (β1(β2TMDV)AR) or single amino acids of TMDV of the β2AR were prepared and stably expressed in Chinese Hamster Ovary cells. Concentration-effect curves for 
cyclicAMP accumulation were carried out for (-)-CGP12177 in the absence or presence of (-)-bupranolol.  
Results. The potencies (pEC50) of (-)-CGP12177 were β2AR (9.24 ± 0.14, n = 5), β1(V230I)AR (9.07 ± 0.07, n = 
10), β1(β2TMDV)AR (8.86 ± 0.10, n = 15), β1(R222Q)AR (8.09 ± 0.29, n = 6), β1AR (8.00 ± 0.11, n = 11). The 
affinities (pKB) of (-)-bupranolol were β2AR (9.82 ± 0.52, n = 5), β1(V230I)AR (7.64 ± 0.12, n = 8), β1(β2TMV)AR 
(8.06 ± 0.17, n = 8), β1(R222Q)AR (7.33 ± 0.23, n = 5), β1AR (7.23 ± 0.23, n = 5).  
Discussion. The potency of (-)-CGP12177 was higher at β2AR than at β1AR consistent with activation through a low 
affinity site at the β1AR (β1LAR). The presence of V230 in β1AR accounted for the lower potency of (-)-CGP 12177. 
The affinity of (-)-bupranolol was lower at β1AR compared to β2AR. The presence of V230 in β1AR accounted in 
part for the lower affinity. In conclusion TMDV of the β1AR contributes in part to the low affinity binding site of β1AR.  
 
